IDEXX Laboratories, Inc. vs Nokia Corp — how do they compare? IDEXX Laboratories, Inc. trades at $516.84 (market cap $40.43B), while Nokia Corp trades at $10.34 (market cap $56.99B). The key difference: Nokia Corp is the larger of the two by market cap, and Nokia Corp pays a 1.61% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Nokia Corp for 66 Days on average.
| IDXX | NOK | |
|---|---|---|
Market Cap | $40.43B | $56.99B |
Volume | 692,164 | 69,968,204 |
Sector | Health | Technology |
52-Week High | $766.68 | $16.83 |
52-Week Low | $504.70 | $5.18 |
Typical Hold Time | 46 Days | 66 Days |
Enterprise Value | $41.32B | $55.01B |
Dividend Yield | — | 1.61% |
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.
The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.
Nokia (NOK) trades at $10.285, down 3.15% today, with a bearish technical signal from moving averages and neutral oscillators. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $19.89B with a net income margin of 3.47%. Recent news highlights partnerships in AI and satellite communications, including an expanded collaboration with Microsoft and a defense-focused satellite venture with ICEYE.
The stock presents a valuation challenge with a high P/E of 75.09, though analyst consensus is bullish with a $17.50 price target. Upside potential is supported by AI infrastructure demand and strategic partnerships, but risks include competitive pressures, execution on growth initiatives, and volatile cash flows. The current price is well below the consensus target, indicating significant projected upside if growth catalysts materialize.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →